Vascular and platelet responses to aspirin in patients with coronary artery disease

European Journal of Clinical Investigation

Volumn 43, Issue 1, 2013, Pages 91-99

  Blann, Andrew D ^a   Kuzniatsova, Nadya ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aspirin resistance; Coronary artery disease; CRP; D dimers; Flow cytometry; P selectin; Platelet aggregation; Vascular function

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; D DIMER; DUAL SPECIFICITY PHOSPHATASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIN; INTERLEUKIN 6; PADGEM PROTEIN; THROMBOPLASTIN; THROMBOXANE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

AGED; ANALYSIS OF VARIANCE; ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; VASCULAR STIFFNESS;

EID: 84871616417     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12021     Document Type: Article

References (51)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trails of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829-43.
3. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009;5:965-72.
4. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120:631-5.
5. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
6. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011;107:339-42.
7. Storey R. Variability of response to antiplatelet therapy. Eur Heart J Supp 2008;10:A21-7.
8. Lee P, Chen W, Ng W, Cheng X, Kwok JY, Tse HF et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-7.
9. Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52.
10. Rajendran S, Parikh D, Shugman I, French JK, Juergens CP. High on treatment platelet reactivity and stent thrombosis. Heart Lung Circ 2011;20:525-31.
11. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, Verify Now, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010;56:839-47.
12. Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM. Pro-Thrombosis Ancillary Study Group. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care 2009;32:944-9.
13. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
14. Lim HS, Lip GY. Arterial stiffness: beyond pulse wave velocity and its measurement. J Hum Hypertens 2008;22:656-8.
15. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
16. Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie 2009;29:32-8.
17. Roldán V, Marín F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003;90:1007-20.
18. Matsumoto M, Nukada T, Uyama O, Yoneda S, Imaizumi M, Miyamoto T et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. Thromb Haemost 1980;44:16-22.
19. 2 after low-dose aspirin. N Engl J Med 1981;304:76-9.
20. Karim S, Habib A, Lévy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996;271:12042-8.
21. Wu KK, Sanduja R, Tsai AL, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A 1991;88:2384-7.
22. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007;49:1957-64.
23. Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008;52:1826-33.
24. Malinin AI, Callahan KP, Serebruany VL. Paradoxical activation of major platelet receptors in the methadone-maintained patients after single pill of aspirin. Thromb Res 2001;104:297-9.
25. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9.
26. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterization of platelet function. Thromb Haemost 1998;79:885-96.
27. Gunarathne A, Patel JV, Hughes EA, Lip GY. Measurement of stiffness index by digital volume pulse analysis technique: clinical utility in cardiovascular disease risk stratification. Am J Hypertens 2008;21:866-72.
28. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121:505-11.
29. Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension 2003;42:1-7.
30. Fuchs I, Frossard M, Spiel A, Riedmüller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-52.
31. Crutchley DJ. Effects of inhibitors of arachidonic acid metabolism on thromboplastin activity in human monocytes. Biochem Biophys Res Commun 1984;119:179-84.
32. Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011;6:e25595.
33. Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010;3:828-35.
34. Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009;102:404-11.
35. Hubl W, Assadian A, Lax J, Meixner U, Fang IF, Hagmüller G et al. Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry. Thromb Res 2007;121:135-43.
36. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
37. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
38. Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther 2011;29:301-7.
39. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006;97:38-43.
40. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
41. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010;8:2140-8.
42. Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007;98:201-9.
43. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34.
44. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24:2166-79.
45. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla VoltaS. Adenosine diphosphate-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost 1986;56:147-50.
46. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993;82:505-12.
47. Pernerstorfer T, Stohlawetz P, Stummvoll G, Kapiotis S, Szekeres T, Eichler HG et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol 1998;102:1229-31.
48. Holowatz LA, Kenney WL. Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans. J Appl Physiol 2009;106:500-5.
49. Reference ValuesforArterialStiffness'Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010;31:2338-50.
50. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A et al. Inter-individual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-35.
51. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.